Navigation Links
Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Date:2/5/2008

onal Technidyne Corporation (ITC) Division increased 5 percent vs. the same period a year ago, with particular growth internationally and from our ProTime(R) System used in physicians' offices or patients' homes to monitor anticoagulation therapy," said Gary F. Burbach, president and chief executive officer of Thoratec.

"Clearly, the highlight of the quarter was the unanimous recommendation by the FDA Circulatory System Devices Advisory Panel on November 30 that the agency approve, with conditions, our PMA (PreMarket Approval) allowing the use of our HeartMate II for Bridge to Transplant," Burbach noted.

"It was the panel's view that the trial data demonstrated the safety and efficacy of the device, and we believe that the conditions outlined in their recommendations will not limit our ability to increase adoption of the HeartMate II. We have been engaged in a productive process with the FDA since then, and by the end of the week we expect to have submitted all the information the FDA has requested with respect to labeling, the development of an appropriate post-approval study and updates to patient data, and believe we are on track for approval and launch at the end of this quarter," he continued.

As of January 25, 2008, enrollment in the Destination Therapy arm was 479 patients, an increase of 53 patients over the 426 patients three months ago. Enrollment in the randomized portion of the DT arm of the trial was 291 patients, versus 265 patients three months ago. Two year follow up on the pivotal 200 randomized Destination Therapy patients will be complete in May 2009. Enrollment in the BTT arm of the trial was 439 patients, compared with 390 patients as of October 26, 2007.

Total enrollment in the Pivotal trial as of January 25 was 918 patients versus 816 three months ago, and an increase of 415 patients over the 503 patients enrolled a year ago.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $234.8 million in 2007 com
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Thoratec Presentation at JP Morgan Conference to be Webcast
2. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
3. Thoratec Presentation at Bear Stearns Conference To Be Webcast
4. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
9. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 PMG Research, ... Board. PMG Research is a network of sites that provide ... to over 2 million patient lives through its partnerships with ... comprised of 11 hub site locations in the Southeastern United ... first term of the board will be held ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) ... Alliance , provider of clinical research and data management ... addition to its CRO Partnership Program, Clinovo expands ... India. , “We have found Clinovo’s ClinCapture to ... platform which is both user friendly and easy to ...
(Date:11/26/2014)... Global biostimulants market is expected to reach ... CAGR of 12.5%. In order to cater to ... ecological impacts, farmers are looking to adopt natural ... more effectively & efficiently. Biostimulants are consequently seen ... on investments. , Leading companies in the biostimulants ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4
... University of California, Berkeley, have developed a pressure-sensitive electronic ... new meaning to the term "thin-skinned." "The ... the human skin, which means incorporating the ability to ... of electrical engineering and computer sciences and head of ...
... Spotlights Innovations During ESTRO29 -- VEENENDAAL, The Netherlands, September 10, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... lure of greater profits elsewhere in the world may ... and distribution of affordable drugs, vaccines and diagnostics for ... millions of poor people, experts warn. And they ... support for continuing the success of firms finding homegrown ...
Cached Biology Technology:Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3Nucletron Spotlights Innovations During ESTRO29 2Nucletron Spotlights Innovations During ESTRO29 3Nucletron Spotlights Innovations During ESTRO29 4Nucletron Spotlights Innovations During ESTRO29 5Nucletron Spotlights Innovations During ESTRO29 6Nucletron Spotlights Innovations During ESTRO29 7Global health vs. global wealth: Looming choice for health firms in developing countries 2Global health vs. global wealth: Looming choice for health firms in developing countries 3Global health vs. global wealth: Looming choice for health firms in developing countries 4
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... Scientists at Joslin Diabetes Center have identified biological mechanisms ... against kidney disease, and also mechanisms that inhibit its ... online by Diabetes, may lead to the development of ... to prevent the harmful effects of hyperglycemia on renal ...
... melanoma is a malignant form of skin cancer and ... there is. Treatment is particularly difficult, because melanomas are ... Chris Marine, (VIB/KU Leuven) have found a new line ... cancers, namely by combating the interaction between the protein ...
... observes a colorful jellyfish pulsating through the ocean, Greek ... animal once was known as the medusa, after the ... gaze turned people into stone, and now, thanks to ... researchers at the California Institute of Technology (Caltech) and ...
Cached Biology News:Joslin researchers gain new understanding of diabetes and kidney disease 2Joslin researchers gain new understanding of diabetes and kidney disease 3New line of approach for combination therapy against melanoma 2Medusa reimagined: Caltech-led team reverse engineers a jellyfish with the ability to swim 2Medusa reimagined: Caltech-led team reverse engineers a jellyfish with the ability to swim 3Medusa reimagined: Caltech-led team reverse engineers a jellyfish with the ability to swim 4
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
Biology Products: